Table 1. OS and RFS after liver resection in patients with HCC and only PVTT (not inclusive of patients with HVTT).
| Country/region | n/n | 1-year, % (95% CI) | P | n/n | 3-year, % (95% CI) | P | n/n | 5-year, % (95% CI) | P |
|---|---|---|---|---|---|---|---|---|---|
| OS* | |||||||||
| Global | 20/3,806 | 51.77 (40.71–62.65) | – | 16/3,592 | 20.16 (11.52–32.87) | – | 9/2,487 | 21.19 (11.16–36.54) | – |
| By country/region* | |||||||||
| China | 15/3,411 | 46.68 (34.93–58.81) | <0.0001 | 12/3,228 | 15.65 (7.69 – 29.23) | <0.0001 | 6/2,166 | 18.25 (8.15 – 35.95) | <0.0001 |
| Japan | 1/29 | 62.10 (43.62–77.63) | 1/29 | 24.10 (11.94–42.65) | 1/29 | 17.20 (7.34–35.27) | |||
| Korea | 2/74 | 72.43* (61.21–81.39) | 1/43 | 42.00 (28.33–57.02) | 0/0 | – | |||
| Taiwan | 1/247 | 85.00 (79.98–88.93) | 1/247 | 68.00 (61.93–73.52) | 1/247 | 61.00 (54.78–66.89) | |||
| France | 1/45 | 30.80 (19.12–45.60) | 1/45 | 20.50 (11.11–34.71) | 1/45 | 15.40 (7.49–29.03) | |||
| RFS* | |||||||||
| Global | 11/3,118 | 22.67 (16.97–29.60) | – | 9/3,005 | 7.05 (4.99–9.87) | – | 3/1,763 | 0.65 (0.01–26.72) | – |
| By country* | |||||||||
| China | 8/2,999 | 20.29 (14.27–28.02) | 0.15 | 7/2,917 | 6.22 (4.39–8.75) | 0.04 | 2/1,718 | 0.10** (0.00–31.83) | 0.12 |
| Korea | 2/74 | 31.17 (19.73–45.48) | 1/43 | 16.00 (7.77–30.09) | 0/0 | – | |||
| France | 1/45 | 32.50 (20.51–47.33) | 1/45 | 11.60 (5.01–24.63) | 1/45 | 11.60 (5.01–24.63) | |||
n/n, studies/patients; *, some studies encompassed multiple regions, so they were included in the global analysis but not in the regional/country analysis; **, all I2>65.2 with P value <0.05, except for values marked. OS, overall survival; RFS, recurrence free survival; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombosis.